Share Beyond the Abstract
Share to email
Share to Facebook
Share to X
By Beyond the Abstract
5
2323 ratings
The podcast currently has 41 episodes available.
Humans have long sought the fountain of youth, and recently scientists have explored the biological basis of aging and potential strategies to reverse the process. Along with groundbreaking discoveries that have enabled extending the lifespan of model organisms, the anti-aging movement has spurred an entire industry focused on stopping the biological clock. In today's episode of Beyond the Abstract, Derek and Dan discuss recent studies about the aging process and debate the promises and pitfalls of this fast-moving field.
This episode is sponsored by Proteintech Group, a company that creates reagents for the biomedical sciences so scientists can conduct groundbreaking science. Visit them at www.ptglab.com to find out more.
The information presented here is not medical advice. Consult your physician for any questions regarding your personal health.
Articles Discussed
Abad et al. Reprogramming in vivo produces teratomas and iPS cells with totipotency features. Nature, 2013.
Ross et al. Depleting myeloid-biased haematopoietic stem cells rejuvenates aged immunity. Nature, 2024.
Ocampo et al. In Vivo Amelioration of Age-Associated Hallmarks by Partial Reprogramming. Cell, 2016.
Wang et al. In vivo partial reprogramming of myofibers promotes muscle regeneration by remodeling the stem cell niche. Nature Communications, 2021.
Browder et al. In vivo partial reprogramming alters age-associated molecular changes during physiological aging in mice. Nature Aging, 2022.
Weindruch et al. The retardation of aging in mice by dietary restriction: longevity, cancer, immunity and lifetime energy intake. Journal of Nutrition, 1986.
Lu et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature, 2020.
Yucel and Gladyshev. The long and winding road of reprogramming-induced rejuvenation. Nature Communications, 2024.
Lopez-Otin et al. The Hallmarks of Aging. Cell, 2013.
Choudhury et al. Proline restores mitochondrial function and reverses aging hallmarks in senescent cells. Cell Reports, 2024.
Zeng et al. Restoration of CPEB4 prevents muscle stem cell senescence during aging. Developmental Cell, 2023.
Disorders of the brain are among the most challenging to treat in all of medicine. Among the challenges is access: the brain is locked away in the skull, preventing medicines from reaching their destination. To deal with this difficulty, researchers are turning to an unexpected access point to the brain: the eye. In today's episode of Beyond the Abstract, Derek and Dan discuss new papers that demonstrate neural and immune links between the eye and the brain that could soon help doctors treat diseases ranging from Alzheimer's to cancer.
Articles discussed
Murdock et al., Multisensory gamma stimulation promotes glymphatic clearance of amyloid. Nature. 2024 (https://www.nature.com/articles/s41586-024-07132-6)
Yin et al., Compartmentalized ocular lymphatic system mediates eye-brain immunity. Nature. 2024 (https://www.nature.com/articles/s41586-024-07130-8)
The information presented here is not medical advice. Consult your physician for any questions regarding your personal health.
Food allergies are a major problem – common, potentially deadly, and without effective medicines to prevent them from occurring. But earlier this year, researchers and doctors published a clinical trial reporting an effective new treatment for preventing allergic food reactions. In today’s episode of Beyond the Abstract, Derek and Dan dive into the science behind the new treatment and what it might mean for the future of combating a deadly disease.
Article discussed
Wood et al., Omalizumab for the Treatment of Multiple Food Allergies. New England Journal of Medicine. 2024 (https://www.nejm.org/doi/full/10.1056/NEJMoa2312382)
The information presented here is not medical advice. Consult your physician for any questions regarding your personal health.
Thousands of patients in the US die every year waiting for an organ transplant, often because there are not enough human organ donors. Xenotransplantation — transplantation from another species to humans — could solve this problem, but has remained the realm of science fiction given many technical obstacles. Now, with advances in gene editing, this pipe dream is becoming reality. In today's episode of Beyond the Abstract, Dan and Derek explore xenotransplantation, tell the stories of the few humans who have received pig organs, and explain why this may herald a new era in transplant medicine.
Articles discussed
Griffith et al. Genetically modified porcine-to-human cardiac xenotransplantation. New England Journal of Medicine. 2022. (https://www.nejm.org/doi/full/10.1056/NEJMoa2201422)
Anand et al. Design and testing of a humanized porcine donor for xenotransplantation. Nature. 2023. (https://www.nature.com/articles/s41586-023-06594-4)
The information presented here is not medical advice. Consult your physician for any questions regarding your personal health.
While almost all women experience nausea and vomiting during pregnancy, few are debilitated by severe symptoms: a condition known as hyperemesis gravidarum (HG). HG has been stigmatized and neglected by the biomedical community, with limited research funding for developing effective treatments. In this episode of Beyond the Abstract, Derek and Dan tell the remarkable story of one scientist who experienced HG herself, and her decades-long journey to find a cure.
Articles discussed
Her Doctor Said Her Illness Was All in Her Head. This Scientist Was Determined to Find the Truth. Alice Callahan. New York Times, 2023. (https://www.nytimes.com/2023/03/14/well/marlena-fejzo-hyperemesis-gravidarum.html)
GDF15 linked to maternal risk of nausea and vomiting during pregnancy. Fejzo et al. 2023. Nature. (https://www.nature.com/articles/s41586-023-06921-9).
Placenta and appetite genes GDF15 and IGFBP7 are associated with hyperemesis gravidarum. Fejzo et al. 2018. Nature Communications. (https://www.nature.com/articles/s41467-018-03258-0)
The information presented here is not medical advice. Consult your physician for any questions regarding your personal health.
A new class of medicines has transformed the treatment of obesity -- Wegovy and Ozempic have become household names. While we discussed these GLP-1 medicines on an episode of Beyond the Abstract less than a year ago, the field has progressed so quickly we thought it was already time to review many of these recent developments. In today's episode, Derek and Dan first discuss improved versions of these medicines on the horizon for the treatment of obesity. Derek and Dan then talk about how these medicines are being studied to treat a wide range of diseases outside of obesity, ranging from cardiovascular disease to substance use disorder.
Articles discussed
Jastreboff et al 2023 NEJM, Triple-Hormone Receptor Agonist Retatrutide for Obesity -- A Phase 2 Trial (https://www.nejm.org/doi/full/10.1056/NEJMoa2301972)
Wharton et al 2023 NEJM, Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity (https://www.nejm.org/doi/full/10.1056/NEJMoa2302392)
Lincoff et al 2023 NEJM, Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (https://www.nejm.org/doi/full/10.1056/NEJMoa2307563)
Kosiborod et al 2023 NEJM, Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (https://www.nejm.org/doi/full/10.1056/NEJMoa2306963)
The information presented here is not medical advice. Consult your physician for any questions regarding your personal health.
Debates around artificial intelligence are everywhere: will ChatGPT usher in a new era of productivity and creativity? Or will advanced AI replace millions of workers? Doctors have similar questions about how AI may influence medicine. In today's episode of Beyond the Abstract, Dan and Derek take a deep dive into all things AI and health. They discuss the current role of AI in medicine and the promises and perils of potential new applications made possible because of ChatGPT and other emerging AI technologies.
Moor et al., Foundational models for generalist medical artificial intelligence, Nature, 2023 (https://www.nature.com/articles/s41586-023-05881-4).
He et al., Blinded, randomized trial of sonographer versus AI cardiac function assessment, Nature, 2023 (https://www.nature.com/articles/s41586-023-05947-3).
The information presented here is not medical advice. Consult your physician for any questions regarding your personal health.
It's well known that emotions can affect the heart - we've all had an anxiety-producing thought that leads to the feeling of our heart pounding out of our chest. But what about the opposite: can the heart control our emotions? In today's episode of Beyond the Abstract, Derek and Dan discuss a fascinating new study looking at whether making the heart beat fast can cause anxiety-related behaviors.
Hsueh et al., Cardiogenic control of affective behavioral state, Nature, March 2023 (https://www.nature.com/articles/s41586-023-05748-8)
The information presented here is not medical advice. Consult your physician for any questions regarding your personal health.
The effect of inappropriate blood clotting can be devastating, including heart attack and stroke. While there are many medications to reduce the risk of clotting, our understanding of why blood clots and when remains incomplete. In today’s episode of Beyond the Abstract, Derek and Dan share the remarkable story of how a team of researchers discovered new clotting biology, in a story that begins with a surprising observation about hibernating bears and ends with the characterization of a potential new drug target for humans.
Thienel et al. Immobility-associated thromboprotection is conserved across mammalian species from bear to human. Science, 2023.
The information presented here is not medical advice. Consult your physician for any questions regarding your personal health.
Alzheimer’s disease is a devastating neurodegenerative condition affecting millions of people around the world. Current therapies are only partially effective, despite decades of research aimed at understanding the causes of the disease. Alzheimer’s is largely genetic, and the best-known genetic risk factor for Alzheimer’s comes from mutations in a gene called APOE. Until recently, however, exactly how these mutations increase risk for the disease has not been well understood. In today’s episode, Dan and Derek discuss new research on how mutations in APOE leads to Alzheimer’s disease. They talk about the new biological pathways uncovered, the potential therapeutic potential of the discovery, and a related early-stage clinical trial of gene therapy in Alzheimer’s disease.
Blanchard et al., APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes. Nature, November 2022. DOI: https://doi.org/10.1038/s41586-022-05439-w
The information presented here is not medical advice. Consult your physician for any questions regarding your personal health.
The podcast currently has 41 episodes available.